Nanobiotechnology-based Drug Delivery in Brain Targeting
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Blood brain barrier (BBB) found to act as rate limiting factor in drug delivery to brain in combating the central nervous system (CNS) disorders. Such limiting physiological factors include the reticuloendothelial system and protein opsonization, which present across BBB, play major role in reducing the passage of drug. Several approaches employed to improve the drug delivery across the BBB. Nanoparticles (NP) are the solid colloidal particle ranges from 1 to 1000 nm in size utilized as career for drug delivery. At present NPs are found to play a significant advantage over the other methods of available drug delivery systems to deliver the drug across the BBB. Nanoparticles may be because of its size and functionalization characteristics able to penetrate and facilitate the drug delivery through the barrier. There are number of mechanisms and strategies found to be involved in this process, which are based on the type of nanomaterials used and its combination with therapeutic agents, such materials include liposomes, polymeric nanoparticles and non-viral vectors of nano-sizes for CNS gene therapy, etc. Nanotechnology is expected to reduce the need for invasive procedures for delivery of therapeutics to the CNS. Some devices such as implanted catheters and reservoirs however will still be needed to overcome the problems in effective drug delivery to the CNS. Nanomaterials are found to improve the safety and efficacy level of drug delivery devices in brain targeting. Nanoegineered devices are found to be delivering the drugs at cellular levels through nono-fluidic channels. Different drug delivery systems such as liposomes, microspheres, nanoparticles, nonogels and nonobiocapsules have been used to improve the bioavailability of the drug in the brain, but microchips and biodegradable polymeric nanoparticulate careers are found to be more effective therapeutically in treating brain tumor. The physiological approaches also utilized to improve the transcytosis capacity of specific receptors expressed across the BBB. It is found that the low density lipoproteins related protein (LPR) with engineered peptide compound (EpiC) formed the platform incorporating the Angiopep peptide as a new effective therapeutics. The current challenges are to design and develop the drug delivery careers, which must be able to deliver the drug across the BBB at a safe and effective manner. Nanoparticles are found to be effective careers in delivery of conventional drugs, recombinant proteins, vaccines as well as nucleotides. Nanoparticlulate drug delivery systems are found to be improving in the pharmacokinetic strategies of the drug molecules such as biodistribution, bioavailability and drug release characteristics in a controlled and effective manner with site specific drug delivery targeting to tissue or cell with reduction in toxic manifestation. Therefore, the use of nanotechnology in the field of pharmaceutical biotechnology helps in improving the drug delivery strategy including the kinetics and therapeutic index to solve the delivery problems of some biotech drugs including the recombinant proteins and oligonucleotides. This review is made to provide an insight to the role of nanobiotechnology in drug delivery and drug targeting to brain and its recent advances in the field of drug delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · cited 1×
“PEG may be complexed with PLGA nanoparticles to act as a cover to the hydrophobic PLGA core [36].”
BackgroundNanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 1×
“The primary advantage of NP as a career is able to mask the barrier limiting characteristics of the therapeutic drug molecule and the system as well as able to control the drug release rate in the brain, decreasing the level of toxicity [1].”
BackgroundPardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
de Kozak, Y., Andrieux, K., Villarroya, H., Klein, C., Thillaye‐Goldenberg, B., Naud, M., Garcia, E., & Couvreur, P. (2004) · European Journal of Immunology · doi:10.1002/eji.200425022 · Cited by 130
Nanobiotechnology-based drug delivery to the central nervous system.
Jain, K. K. (2007) · Neurodegenerative Diseases · doi:10.1159/000101884 · Cited by 100 · cited 1×
“com of the Nanomaterials used and its combination with therapeutic moieties, for example the use of liposomes and polymeric nanoparticles [2, 3].”
Method
Cited by
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Leite, P. E. C., Pereira, M. R., Harris, G., Pamies, D., dos Santos, L. M. G., Granjeiro, J. M., Hogberg, H. T., Hartung, T., & Smirnova, L. (2019) · Particle and Fibre Toxicology · doi:10.1186/s12989-019-0307-3 · Cited by 92
Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment
Viegas, C., Pereira, D. S. M., & Fonte, P. (2022) · Materials · doi:10.3390/ma15062086 · Cited by 21
“These capabilities are very important in the case of HNC, because in some cases, to reach the therapeutic target it is necessary cross biological barriers such as the blood–brain barrier, which we know reduces drug delivery to the brain [15].”
Background
Metadata
- Authors
- Dinda, S., & Pattnaik, G.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-06-08
- Volume
- 14
- Issue
- 15
- Pages
- 1264-1274
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2157861529
- Cited by
- 60
- References
- 7
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanobiotechnology-based Drug Delivery in Brain Targeting. https://app.cochat.ai/papers/10.2174/1389201015666140608143719
- The paper
- Dinda, S., & Pattnaik, G. (2014). Nanobiotechnology-based Drug Delivery in Brain Targeting. Current Pharmaceutical Biotechnology. https://doi.org/10.2174/1389201015666140608143719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.